Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 221

The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.

The effect of early treatment with ivermectin on viral load, symptoms and humoral response in patients with non-severe COVID-19: A pilot, double-blind, placebo-controlled, randomized clinical trial

Open access
Chaccour, Carlos, Casellas, Aina, Blanco-Di Matteo, Andrés, Pineda, Iñigo, Fernandez-Montero, Alejandro, Ruiz-Castillo, Paula, Richardson, Mary-Ann, Rodríguez-Mateos, Mariano, Jordán-Iborra, Carlota, Brew, Joe, Carmona-Torre, Francisco, Giráldez, Miriam, Laso, Ester, Gabaldón-Figueira, Juan C., Dobaño, Carlota, Moncunill, Gemma, Yuste, José R., Del Pozo, Jose L., Rabinovich, N.Regina, Schöning, Verena, Hammann, Felix, Reina, Gabriel, Sadaba, Belen, Fernández-Alonso, Mirian · 2021 · EClinicalMedicine

Published version of a preprint

Abstract

Abstract Ivermectin inhibits the replication of SARS-CoV-2 in vitro at concentrations not readily achievable with currently approved doses. There is limited evidence to support its clinical use in COVID-19 patients. We conducted a Pilot, randomized, double-blind, placebo-controlled trial to determine the efficacy of a single dose of ivermectin to reduce the proportion of PCR positives, viral load at day 7 post treatment.Consecutive patients with confirmed severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and mild COVID-19 (no pneumonia) and no risk factors for complicated disease attending the emergency room of the Clínica Universidad de Navarra. Patients were randomized 1:1 to receive ivermectin, 400 mcg/kg, single dose (n = 12) or placebo (n = 12). The primary outcome measure was the proportion of patients with detectable SARS-CoV-2 RNA by PCR from nasopharyngeal swab at day 7 post-treatment. The primary outcome was supported by determination of the viral load and infectivity of each sample. The differences between ivermectin and placebo were calculated using Fisher’s exact test and presented as a relative risk ratio.All patients recruited completed the trial (median age, 26 [range, 18-54] years; 12 [50%] women; 100% had symptoms at recruitment, 70% reported headache, 62% reported fever, 50% reported general malaise and 25% reported cough). At day 7, there was no difference in the proportion of PCR positive patients (RR 0.92, 95% CI: 0.77-1.09, p = 1.0). The ivermectin group had lower median viral loads at days 4 and 7 post treatment as well as lower median IgG titers at day 21 post treatment. Hyposmia/anosmia (76 vs 158 patient-days) and cough (68 vs 97 patient-days) were less frequent in the ivermectin group.Among patients with mild COVID-19 and no risk factors for severe disease receiving a single 400 mcg/kg dose of ivermectin within 48 hours of fever or cough onset there was no difference in the proportion of PCR positives. There was however a marked reduction of anosmia/hyposmia, a reduction of cough and a tendency to lower viral loads and lower IgG titers which warrants assessment in larger trials.Trial registration ClinicalTrials.gov Identifier: NCT04390022 https://clinicaltrials.gov/ct2/show/NCT04390022

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.eclinm.2020.100720

Cites

3 of 3 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Research works printed but not linked: 31

  1. Rubin, 2020, Difficult to determine herd immunity threshold for COVID-19, JAMA, 324, 732
  2. Fontanet, 2020, COVID-19 herd immunity: where are we?, Nat Rev Immunol, 20, 583, 10.1038/s41577-020-00451-5 · DOI · Paper page
  3. Wagstaff, 2012, Ivermectin is a specific inhibitor of importin alpha/beta-mediated nuclear import able to inhibit replication of HIV-1 and dengue virus, Biochem J, 443, 851, 10.1042/BJ20120150 · DOI · Paper page
  4. Barrows, 2016, A screen of FDA-approved drugs for inhibitors of Zika virus infection, Cell Host Microbe, 20, 259, 10.1016/j.chom.2016.07.004 · DOI · Paper page
  5. Mastrangelo, 2012, Ivermectin is a potent inhibitor of flavivirus replication specifically targeting NS3 helicase activity: new prospects for an old drug, J Antimicrob Chemother, 67, 1884, 10.1093/jac/dks147 · DOI · Paper page
  6. Caly, 2020, The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro, Antiviral Res, 178, 10.1016/j.antiviral.2020.104787 · DOI · Paper page
  7. Ahmed, 2020, A five day course of ivermectin for the treatment of COVID-19 may reduce the duration of illness, Int J Infect Dis
  8. Krolewiecki A, Lifschitz A, Moragas M, et al. Antiviral effect of high-dose ivermectin in adults with COVID-19: a pilot randomised, controlled, open label, multicentre trial. http://dx.doi.org/10.2139/ssrn.3714649 (accessed Nov 2020). · DOI
  9. Rajter, 2020, Use of ivermectin is associated with lower mortality in hospitalized patients with coronavirus disease 2019: the ICON study, Chest
  10. Chaccour, 2020, Trials, 21, 498, 10.1186/s13063-020-04421-z · DOI
  11. Rhee, 2020, Duration of SARS-CoV-2 infectivity: when is it safe to discontinue isolation?, Clin Infect Dis
  12. Benefield, 2020, SARS-CoV-2 viral load peaks prior to symptom onset: a systematic review and individual-pooled analysis of coronavirus viral load from 66 studies, medRxiv
  13. He, 2020, Temporal dynamics in viral shedding and transmissibility of COVID-19, Nat Med
  14. Gomez-Ambrosi, 2012, Body mass index classification misses subjects with increased cardiometabolic risk factors related to elevated adiposity, Int J Obes (Lond), 36, 286, 10.1038/ijo.2011.100 · DOI · Paper page
  15. Bray, 2020, Ivermectin and COVID-19: a report in antiviral research, widespread interest, an FDA warning, two letters to the editor and the authors' responses, Antiviral Res, 10.1016/j.antiviral.2020.104805 · DOI
  16. Arshad, 2020, Prioritization of anti-SARS-Cov-2 drug repurposing opportunities based on plasma and target site concentrations derived from their established human pharmacokinetics, Clin Pharmacol Ther, 108, 775, 10.1002/cpt.1909 · DOI
  17. Hoffmann, 2020, Chloroquine does not inhibit infection of human lung cells with SARS-CoV-2, Nature, 585, 588, 10.1038/s41586-020-2575-3 · DOI · Paper page
  18. de Melo, 2020, Anti-COVID-19 efficacy of ivermectin in the golden hamster, bioRxiv
  19. Marklund, 2020, Serum-IgG responses to SARS-CoV-2 after mild and severe COVID-19 infection and analysis of IgG non-responders, PLoS One, 15, 10.1371/journal.pone.0241104 · DOI · Paper page
  20. Changeux, 2020, A nicotinic hypothesis for Covid-19 with preventive and therapeutic implications, C R Biol, 343, 33, 10.5802/crbiol.8 · DOI · Paper page
  21. Torabi, 2020, Proinflammatory cytokines in the olfactory mucosa result in COVID-19 induced anosmia, ACS Chem Neurosci, 11, 1909, 10.1021/acschemneuro.0c00249 · DOI · Paper page
  22. Schaller, 2017, Dual anti-inflammatory and anti-parasitic action of topical ivermectin 1% in papulopustular rosacea, J Eur Acad Dermatol Venereol, 31, 1907, 10.1111/jdv.14437 · doi:10.1111/jdv.14437
  23. Thibaut de Ménonville, 2017, Topical treatment of rosacea with ivermectin inhibits gene expression of cathelicidin innate immune mediators, LL-37 and KLK5, in reconstructed and ex vivo skin models, Dermatol Ther (Heidelb), 7, 213, 10.1007/s13555-017-0176-3 · DOI
  24. Kahlenberg, 2013, Little peptide, big effects: the role of LL-37 in inflammation and autoimmune disease, J Immunol, 191, 4895, 10.4049/jimmunol.1302005 · DOI · Paper page
  25. Han, 2015, MeTC7, a novel vitamin D receptor (VDR) antagonist, induces cytotoxicity in metastatic melanoma cell lines and inhibits importin-mediated VDR nuclear transport and signaling, J Am Acad Dermatol, 72, AB172, 10.1016/j.jaad.2015.02.705 · doi:10.1016/j.jaad.2015.02.705
  26. Wagstaff, 2012, Ivermectin is a specific inhibitor of importin α/β-mediated nuclear import able to inhibit replication of HIV-1 and dengue virus, Biochem J, 443, 851, 10.1042/BJ20120150 · DOI · Paper page
  27. Miyauchi, 2005, Importin 4 is responsible for ligand-independent nuclear translocation of vitamin D receptor, J Biol Chem, 280, 40901, 10.1074/jbc.M509347200 · doi:10.1074/jbc.m509347200
  28. Gombart, 2009, The vitamin D-antimicrobial peptide pathway and its role in protection against infection, Fut Microbiol, 4, 1151, 10.2217/fmb.09.87 · DOI · Paper page
  29. Chaccour, 2020, Nebulized ivermectin for COVID-19 and other respiratory diseases, a proof of concept, dose-ranging study in rats, Sci Rep, 10, 17073, 10.1038/s41598-020-74084-y · DOI
  30. Cevik, 2020, SARS-CoV-2, SARS-CoV, and MERS-CoV viral load dynamics, duration of viral shedding, and infectiousness: a systematic review and meta-analysis, Lancet Microbe
  31. Dahdouh, 2020, Ct values from SARS-CoV-2 diagnostic PCR assays should not be used as direct estimates of viral load, J Infect

Cited by

See all 221

Metadata

Authors
Chaccour, C., Casellas, A., Blanco-Di Matteo, A., Pineda, I., Fernandez-Montero, A., Ruiz-Castillo, P., Richardson, M.-A., Rodríguez-Mateos, M., Jordán-Iborra, C., Brew, J., Carmona-Torre, F., Giráldez, M., Laso, E., Gabaldón-Figueira, J. C., Dobaño, C., Moncunill, G., Yuste, J. R., Del Pozo, J. L., Rabinovich, N. R., Schöning, V., Hammann, F., Reina, G., Sadaba, B., & Fernández-Alonso, M.
Venue
EClinicalMedicine
Publisher
Elsevier BV
Published
2021-02
Volume
32
Pages
100720
ISSN
2589-5370 (ISSN-L)
OpenAlex
W3111068209
Cited by
221
References
3
FWCI
15.40
Type
journal article
Language
en
Open access
gold
Licence
Funders
Barcelona Institute of Science and Technology

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.